UNCY · Unicycive Therapeutics Inc
United States · RS rating 16 · As of 2026-11-03
| Price | 3.59 USD |
|---|---|
| 1-day change | +2.9% |
| RS rating (overall / 1M / 3M / 12M) | 16 / 28 / 20 / 34 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 4 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +88.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +58.1% |
| Market cap (USD) | $185.5M |